Covid Vaccination Argentina

[gracielle]

29 January 2022

Qué inmunidad provee cada tipo de vacuna | Las vacunas de ARN mensajero parecen ser más efectivas para prevenir la infección y las de vectores virales lo serían para reducir la mortalidad

Un estudio internacional realizado en Dinamarca, del que participaron dos científicos argentinos, confirmó la seguridad y eficacia de la inmunización contra el coronavirus y aseguró que las vacunas de ARN mensajero “parecieran ser más efectivas para pr...

www.pagina12.com.ar

What immunity each type of vaccine provides? An international study carried out in Denmark, in which two Argentine scientists participated, confirmed the safety and efficacy of immunization against coronavirus and assured that mRNA vaccines "seem to be more effective in preventing symptomatic infection" while those using viral vectors would be "more effective in reducing mortality". The research work, published this week in the specialized journal Plos One, was led by researchers from the Copenhagen Trial Unit and signed by scientists from Canada, the United Kingdom, Zambia, Nigeria and two Argentines, members of the Institute of Clinical and Health Effectiveness (IECS).

The scientific study states that "the efficacy in the prevention of covid-19 was 95% for mRNA vaccines; 61% for inactivated vaccines (such as those of Sinovac and Sinopharm); 77% for those of protein subunits (such as Novavax) and 68% for those of viral vectors (such as Sputnik V or those of AstraZeneca and J&J/Janssen)". Meanwhile, "when their ability to prevent deaths was assessed, all the vaccines were shown to be more effective than placebos or controls, but the viral vector vaccines had the most marked effect". To carry out the report, the specialists analyzed 35 investigations on vaccines from different platforms, published up to June 17, 2021, and used a methodology called "living systematic review with sequential analysis of trials and a network meta-analysis", which allows synthesizing all previous publications on the subject and making comparisons of efficacy and safety between different products", the IECS said in a press release....

 

[gracielle]

30 January 2022

Sputnik V: El ministro de Salud de Rusia le confirmó a Vizzotti la fecha en que se enviarán los documentos a la OMS | La aprobación del inmunizante ruso

El ministro de Vladimir Putin agradeció a Vizzotti el apoyo argentino en pos de que la OMS incluya a la Sputnik V en la lista de emergencia. La ministra argentina se comprometió recientemente con el director general del organismo a brindar los datos de...

www.pagina12.com.ar

Sputnik V: Russia's Health Minister confirmed to Carla Vizzotti the date when documents will be sent to the WHO and thanked her for Argentina's support towards the inclusion of Sputnik V in emergency list of the organization....The National Minister of Health met with her Russian counterpart, Michail Muraško. The meeting discussed the delay in the approval of the Sputnik V vaccine by the WHO. The Argentine Minister recently made a commitment to the Director General of the WHO to provide data on the effectiveness and safety of the Russian vaccine in Argentina, where it has been applied to more than 15 million people. Muraško anticipated to Vizzotti that his country will submit the documentation to the WHO before the end of the month and that there will be a visit by technicians from the organization to the plants where the Russian vaccine is produced. He also told the Argentinean official that Russia started to vaccinate adolescents between 12 and 17 years of age, and congratulated Vizzotti for the progress made in the inoculation of minors in Argentina....Next week, the Minister will have a virtual meeting with the technical teams of the Russian Ministry of Health to show the effectiveness data of the heterologous schemes carried out in Argentina.

 

[gracielle]

31 January 2022

Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine

The FDA approved a second COVID-19 vaccine, Spikevax. Spikevax is approved for the prevention of COVID-19 in individuals 18 years of age and older.

www.fda.gov

Today, the U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.

FDA Approves First COVID-19 Vaccine

FDA approved the first COVID-19 vaccine, now marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older.

www.fda.gov

On 23 Aug 2021, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee)....

 

[gracielle]

1 February 2022

Covid-19: cuáles son los barbijos de calidad y qué diferencia tienen con los de tela | La efectividad de cada tipo de tapabocas

No todos los barbijos protegen del mismo modo de la covid-19. La guía de especialistas sobre sus cualidades y la recomendación de cómo deben colocarse.

www.pagina12.com.ar

The effectiveness of each type of face mask. Covid-19: what are the quality face masks and how do they differ from cloth masks?
....The effectiveness of different masks. Recently, the U.S. Centers for Disease Control and Prevention (CDC) released new guidance on which masks are most effective in preventing coronavirus transmission and advised against the use of cloth masks because they give "the least protection". "Loose-fitting cloth products offer the least protection, layered thin fabric products offer the most protection, well-fitting disposable surgical masks and KN95s offer even more protection, and well-fitting National Institute for Occupational Safety and Health-approved filtration masks (including N95s) offer the highest level of protection".

Which cloth masks can be used and what conditions they should meet according to the CDC:
Have multiple layers and be made of a tightly woven fabric.
Have a wire at the nose.
Fit over the nose, chin and sides of the face.
Filter light when the mask is held up against a light source.
Masks that have a cape or include a valve are not recommended.

N95 and Surgical Masks:
The most effective masks remain the N95s, which at the beginning of the pandemic were intended exclusively for health care workers because there was insufficient availability in the marketplace. These masks have the ability to filter out 95% of airborne particles when worn correctly: close-fitting, clean and dry. According to CDC guidance, disposable surgical masks are another good option, as long as they fit properly over the bridge of the nose and chin and do not leak air through the sides. They also recommend masks that fit over the back of the head instead of the
ears. They also indicated that a surgical mask can be combined with a fabric mask to improve the fit and that elastic knots can be tied behind the ears.

CONICET Atom-Protect Masks: They were developed by scientists from the National University of San Martín, the University of Buenos Aires (UBA) and the Conicet, together with the textile company Kovi S.R.L., have been in use in Argentina since 2020. The first model of the mask had a triple layer of protection- antibacterial, antiviral and antifungal- and a durability equivalent to 15 disposable masks. The mask was later improved with another model containing four layers of protection: an external semi-waterproofing layer that slows the entry of micro-droplets; a second layer of woven polyester cotton fabric with the same antiviral active ingredients as the first model of masks; a third physical filter of non-woven fabric with a filtering capacity, certified by Nelson Labs (a leading U.S.-based laboratory testing provider), of 97.1% for dusts from 0.1 µm (micrometers) and 99.9% for aqueous sodium chloride aerosols; and finally, a layer of woven polyester cotton fabric with the same bactericidal and fungicidal actives as the original Atom-Protect.

 

[gracielle]

1 February 2022 at 5:27pm

Coronavirus en Argentina: siguen cayendo los contagios y se reportaron otras 240 muertes

El Ministerio de Salud informó que se registraron 49.122 nuevos casos, menos de la mitad que el martes de la semana pasada.

www.clarin.com

....The Malbrán Institute confirmed this Tuesday the first case of the BA.2 sublineage of Omicron in Argentina. It is a new "version", of common origin, with the coronavirus variant that triggered the contagions in our country. But with so many other distinctive mutations that science stopped to reason whether they should really be talking about another variant.

It is about a 62-year-old man, Argentinean, resident in the City of BA, who returned on January 12 from Uruguay and two days later began to present symptoms compatible with Covid. "The epidemiological data we have from countries where this sub-variant started to become dominant are early, preliminary and correlational, that is, we do not know if there is a causality (of the extent of the increase in cases). They are not conclusive", says to Clarín Humberto Debat, member of Proyecto PAÍS (Proyecto Argentino Interinstitucional de Genómica). A key examination for the analysis of the BA.2 sublineage is Denmark. More than 85% of the infections in its population are due to this "reversion" of Omicron. At the end of the year, they accounted for only 20% of infections. Two weeks into January, 40%.

"So far the World Health Organization (WHO) only mentioned in its January 25 update that a number of countries have recently reported an increase in the prevalence of the BA.2 sequence, but has not yet classified it as either of concern or of interest," Debat said.

 

[gracielle]

13 January 2022 by Elie Dolgin

Omicron thwarts some of the world’s most-used COVID vaccines

Inactivated-virus vaccines elicit few, if any, infection-blocking antibodies — but might still protect against severe disease.

www.nature.com

Omicron thwarts some of the world’s most-used COVID vaccines. Inactivated-virus vaccines elicit few, if any, infection-blocking antibodies — but might still protect against severe disease....

28 January 2022 by Emily Waltz

Does the world need an Omicron vaccine? What researchers say

Public-health specialists are debating the need for a shot targeting the variant, now causing a record-breaking surge in COVID-19 cases.

www.nature.com

Does the world need an Omicron vaccine? What researchers say. Public health specialists are debating the need for a shot targeting the variant, now causing a record-breaking surge in COVID-19 cases....

 

[gracielle]

3 February 2022

German expert panel backs Novavax COVID jab – DW – 02/03/2022

Germany's expert panel on vaccine use (the StiKo) recommends the protein-based jab as a first vaccination for adults, but says booster shots should be mRNA vaccines.

www.dw.com

5 February 2022

COVID digest: Omicron booster may not be needed, study finds – DW – 02/05/2022

A study in monkeys suggested an omicron-specific booster was not significantly different from Moderna's conventional booster. The US passed the grim milestone of 900,000 COVID deaths. DW has the latest.

www.dw.com

 

[MilHojas]

Buenos Aires Province targets youngsters with 'Night of the Vaccines' push

Buenos Aires Province launches Friday night campaign to reach youngsters, as it looks to expand Covid-19 vaccination in region.

batimes.com.ar

 

[gracielle]

7 February 2022

Por qué las vacunas pueden generar síntomas similares al COVID prolongado

Los científicos están investigando por qué en casos aislados se produce, tras la vacunación, niebla mental, dolores de cabeza y cambios en la presión arterial habituales en el long COVID

www.infobae.com

Why vaccines can generate symptoms similar to prolonged COVID. Scientists are investigating why, in isolated cases, mental fog, headaches and changes in blood pressure common in long COVID occur after vaccination. Some people justify their hesitancy about COVID-19 vaccines by saying they fear possible long-term effects or some as yet undetected consequences. But is that really true? A paper recently published in the journal Science analyzes a body of data around the possibility of providing an answer....

Science | AAAS

www.science.org

21 January 2022....This story has been updated with comments from the U.S. Food and Drug Administration and the European Medicines Agency.

 

[D.B. Cooper]

Hi All!

I know some of you were curious about the booster, here's the email I received today:

(Took a few tries to book it, going Friday, I'll get Moderna apparently as my booster)

View attachment 8081

I got my booster shot a few hours ago. I got the Pfizer Vax.